The albumin and monoclonal protein ratio as prognostic marker for multiple myeloma in the era of novel agents

Pathology and Oncology Research

Volumn 18, Issue 3, 2012, Pages 557-561

  Kádár, Katalin ^a   Wolf, Krisztina ^b   Tábori, Judit ^b   Karádi, István ^b   Várkonyi, Judit ^b  

^a SEMMELWEIS UNIVERSITY   (Hungary)

^b SEMMELWEIS UNIVERSITY OF MEDICINE   (Hungary)

Author keywords

A M ratio; Albumin; M protein; Multiple myeloma; Prognostic factors

Indexed keywords

ALBUMIN; ANGIOGENESIS INHIBITOR; BORTEZOMIB; IMMUNOGLOBULIN A; IMMUNOGLOBULIN D; IMMUNOGLOBULIN G; IMMUNOGLOBULIN KAPPA CHAIN; IMMUNOGLOBULIN LAMBDA CHAIN; IMMUNOGLOBULIN M; PROTEINASE INHIBITOR; THALIDOMIDE;

ADULT; AGED; ALBUMIN AND MONOCLONAL PROTEIN RATIO; AMWBC SCORE; ARTICLE; CANCER PROGNOSIS; FEMALE; HUMAN; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; ONCOLOGICAL PARAMETERS; OVERALL SURVIVAL; RETROSPECTIVE STUDY; SCORING SYSTEM; SURVIVAL TIME;

AGED; AGED, 80 AND OVER; ALBUMINS; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; MYELOMA PROTEINS; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 84863989946     PISSN: 12194956     EISSN: 15322807     Source Type: Journal    
DOI: 10.1007/s12253-012-9506-z     Document Type: Article

References (21)

1. Rajkumar SV (2009) Multiple myeloma. Curr Probl Cancer 1:7-64
2. Kyle RA (1983) Long-term survival in multiple myeloma. N Engl J Med 308:314-316
3. Bataille R, Durie BG, Grenier J (1983) Serum beta-2 microglobulin and survival duration in multiple myeloma: a simple reliable marker for staging. Br J Haematol 55:439-447
4. Bataille R, Boccadoro M, Klein et al (1992) C-reactive protein and beta-2 microglobulin produce a simple and powerful myeloma staging system. Blood 80:733-737
5. Eleutherakis-Papaiakovou V, Bamias A, Gika D et al (2007) Renal failure in multiple myeloma: incidence, correlations, and prognostic significance. Leuk Lymph 48:337-341
6. Fonseca R, Barlogie B, Bataille R et al (2004) Genetics and cytogenetics of multiple myeloma: a workshop report. Cancer Res 64:1546-1558
7. Greipp PR, Witzig TE, Gonchoroff NJ et al (1987) Immunofluorescence labelling indices in myeloma and related monoclonal gammopathies. Mayo Clin Proc 62:969-977
8. San Miguel JF, Fonseca R, Greipp PR (2004) Prognostic factors and classification for multiple myeloma: contribution to clinical management. In: Malpas JS, Bergsagel DE, Kyle RA, Anderson KC (eds) Myeloma: Biology and management, 3rd edn. Saunders, Elsevier Inc, Oxford, pp 189-199
9. Witzig TE, Gertz MA, Lust JA et al (1996) Peripheral blood monoclonal plasma cells as a predictor of survival in patients with multiple myeloma. Blood 88:1780-1787
10. Bladé J, Rozman C, Cervantes F et al (1989) A new prognostic system for multiple myeloma based on easily available parameters. Br J Haematol 59:113-118
11. Cavo M, Galieni P, Zuffa E et al (1989) Prognostic variables and clinical staging in multiple myeloma. Blood 74:1778-1780
12. Durie BG, Salmon SE (1975) A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer 36:842-854
13. Greipp PR, Katzman JA, O'Fallon WM et al (1988) Value of beta- 2 microglobulin and plasma cell labelling indices as prognostic factors in patients with newly diagnosed myeloma. Blood 72:219-223
14. Greipp PR, San Miguel J, Durie BG et al (2005) International staging system for multiple myeloma. J Clin Oncol 23:3412-3420
15. Jacobson JL, Hussein MA, Barlogie B et al (2003) Southwest Oncology Group. A new staging system for multiple myeloma patients based on the Southwest Oncology Group (SWOG) experience. Br J Haematol 122:441-450
16. Kumar SK, Mihael JR, Buadi FK et al (2009) Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines. Mayo Clin Proc 84(12):1095-1110
17. Medical Research Working Party on Leukemia in Adults (1980) Prognostic features on the third MRC myelomatosis trial. Br J Cancer 42:831-840
18. Merlini G, Waldesnström JG, Jayakar SD (1980) A new improved clinical staging system for multiple myeloma based on analysis of 123 treated patients. Blood 55:1011-1019
19. San Miguel JF, Garcia Sanz R, Gonzalez M et al (1995) A new staging system for multiple myeloma based on the number of Sphase plasma cells. Blood 85:448-455
20. Várkonyi J, Bajzik E, Fazakas A et al (2009) Short or long survival in multiple myeloma. A simple method for determine the prognosis. Pathol Oncol Res 15:383-387
21. Kaplan EL, Meier P (1958) Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481